Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients
Cancer Medicine · 2025
DOI: 10.1002/cam4.71342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Apoorva C Reddy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Neoplasms, Depression, Anxiety, Medical Marijuana. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCATS NIH HHS, National Institutes of Health.
Themen: Onkologische Pflege, Depression
Abstract (Originalsprache)
Introduction
Cancer patients are increasingly turning to cannabis products to modulate physical and psychological symptoms despite limited evidence supporting their efficacy. We aimed to explore cancer patients' self‐reported anxiety and depression symptoms in response to cannabis use.
Methods
This longitudinal study examined how patient‐reported anxiety and depression symptoms varied according to the dose, ratio of tetrahydrocannabinol (THC) to cannabidiol (CBD), and route of administration of cannabis products among cancer patients. Change in self‐reported anxiety and depression symptoms was evaluated in 1962 cancer patients after 30 days of enrollment in the Minnesota Medical Cannabis Program.
Results
Anxiety scores improved more in patients taking higher doses of CBD (> 14.3 mg/day) compared to those taking lower doses (< 4.6 mg/day) and among patients using enteral cannabis products. Depression scores also improved more for patients taking enteral products.
Discussion
Anxiety scores varied according to the dose of cannabis, the ratio of THC to CBD, and the route of administration of cannabis products. In contrast, depression scores only varied according to the route of administration.
Conclusions
This study of cancer patients in Minnesota suggests that patterns of cannabis use that include relatively higher doses of CBD taken enterally may improve the quality of life of cancer survivors who report anxiety and depression. This study constructs a foundation for future research to improve the tailoring of cannabis‐related educational materials to patients' needs and inform the training of healthcare professionals on how to recommend cannabis products for cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Wisconsin, USA.
- Department of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Wisconsin, USA.
- Minnesota Office of Cannabis Management, Analytics Division, Minnesota, USA.
- School of Pharmacy, University of Wisconsin-Madison, Wisconsin, USA.
ORCID-Profile: Apoorva C Reddy
Förderung
- NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Reddy, A. C., Hampton, J. M., Park, S. J., Dickerson, F., Shah, J., Chewning, B., Schmitz, N., & Trentham-Dietz, A. (2025). Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients. Cancer Medicine. https://doi.org/10.1002/cam4.71342
Vancouver
Reddy AC, Hampton JM, Park SJ, Dickerson F, Shah J, Chewning B, et al. Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients. Cancer Medicine. 2025. doi:10.1002/cam4.71342
BibTeX
@article{Reddy2025,
author = {Reddy, Apoorva C and Hampton, John M and Park, Susan J and Dickerson, Faith and Shah, Janvi and Chewning, Betty and Schmitz, Natalie and Trentham-Dietz, Amy},
title = {Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71342}
}
EUVIMED